Edgewell Personal Care Q3 Earnings: Organic Sales Return to Growth, Outlook Narrowed
EPC sits 75% above its 52-week low of $15.725.
Summary
Edgewell Personal Care reported Q3 FY2026 organic sales growth of 1.1% and adjusted EPS of $0.72, in line with expectations. The company narrowed its full-year outlook, maintaining adjusted EPS and EBITDA midpoints, and declared a $0.15 dividend.
Key Events · Earnings and Guidance · EPC
-
Organic Sales Return to Growth
Q3 net sales rose 1.7% to $570.1M; organic sales increased 1.1%, driven by 3.0% growth in North America, offsetting a 1.4% international decline.
-
Adjusted EPS In Line, Restructuring Weighs
Adjusted EPS was $0.72, matching the prior year. GAAP EPS fell to $0.26 from $0.46 due to $24.5M in restructuring charges related to Wet Shave consolidation.
-
Full-Year Outlook Narrowed, Midpoints Unchanged
FY2026 adjusted EPS outlook narrowed to $1.80-$2.00 (prior $1.70-$2.10); adjusted EBITDA $250-$260M (prior $245-$265M). Organic sales now expected flat to +0.5%.
-
Restructuring Charges Elevated
Q3 pre-tax restructuring costs of $24.5M; full-year expected charges increased to ~$92M from $90M, reflecting ongoing Wet Shave manufacturing consolidation.
Analysis · EPC · Industrial Applications And Services
Edgewell Personal Care reported Q3 FY2026 results with organic net sales returning to growth (+1.1%) and adjusted EPS of $0.72, matching the prior year. North America improved meaningfully, driven by Sun, Skin Care, and Grooming. The company narrowed its full-year outlook, keeping adjusted EPS and EBITDA midpoints unchanged, signaling confidence in a back-half recovery. Restructuring charges remain elevated at $24.5M in the quarter as the company consolidates Wet Shave manufacturing. The results come against a backdrop of a recently rejected $30/share takeover offer, adding context to management's standalone growth narrative.
At the time of this filing, EPC was trading at $27.59 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $15.73 to $29.94. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.